Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
41.8M
-
Shares change
-
+5.39M
-
Total reported value, excl. options
-
$167M
-
Value change
-
+$27.2M
-
Put/Call ratio
-
2.3
-
Number of buys
-
63
-
Number of sells
-
-38
-
Price
-
$4.00
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q2 2025
137 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.8M shares
of 67.8M outstanding shares and own 61.66% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.17M shares), Point72 Asset Management, L.P. (7.04M shares), BlackRock, Inc. (4.24M shares), VANGUARD GROUP INC (3.28M shares), ADAMS STREET PARTNERS LLC (3.28M shares), RTW INVESTMENTS, LP (2.68M shares), Vivo Capital, LLC (2.23M shares), Foresite Capital Management VI LLC (1.73M shares), PERCEPTIVE ADVISORS LLC (1.44M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.36M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.